FAM220A

Across TCGA pan-cancer cohorts, FAM220A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FAM220A data layer compared with 24 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher FAM220A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM220A expression acts as an unfavorable survival marker.

LUSC, CESC, and SARC are the cancer types where FAM220A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	II,III,IV	0.127	0.722	<.001	42	view →
CESC	OS	Median	All	0.203	0.798	.001	18	view →
SARC	DFS	Median	All	0.109	0.611	.030	6	view →
COAD	OS	Median	All	0.598	0.872	.028	4	view →
ESCA	DFS	Median	All	0.098	0.503	.008	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FAM220A–LUSC (DFS)

Open the LUSC breakdown →